Market Overview:
The global drugs of UDCA and t-UDCA market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of liver diseases, rising awareness about the benefits of UDCA and t-UDCA, and technological advancements in drug delivery systems. The global drugs of UDCA and t-UDCA market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into t-UDCA and UDCA. On the basis of application, the market is segmented into gallstone removal surgery, hepatopathy treatment (e.g., viral hepatitis), biliary disease treatment (e.g., cholestasis), other applications (e.g., primary sclerosing cholangitis). The North America region dominates this market followed by Europe due to high prevalence rates for liver diseases in these regions coupled with increasing adoption rates for novel therapies such as drugs of UDCA/t-UDAC In terms value contribution,.
Product Definition:
Drugs of UDCA and t-UDCA are the drugs which are used to treat various diseases. The importance of Drugs of UDCA and t-UDCA is that they help in the treatment of various diseases.
t-UDCA:
t-UDCA (1,4-Unanediol DiCaffeine Anhydrous) is a chemical compound of caffeine and unnea. It is a legal dietary supplement in some countries and an over the counter drug in others. t-UDCA has been studied as an adjunctive therapy for improving wakefulness in patients with sleep disorders associated with Parkinson's disease.
UDCA:
Uracil Daytime Chloroacetate is a drug that is sold in the form of crystals for oral consumption. It has the chemical formula (C4H4O2)2Cl and it is also known as 4-Chloro-1,20-dihydroxynaphthoic acid. The chemical was first synthesized by a group of researchers at MIT in Cambridge Massachusetts back in 1960s.
Application Insights:
Based on the application, the global market is segmented into gallstone, hepatopathy, biliary disease and other. The gallstone segment dominated the overall market in 2017 owing to a high incidence rate of acute cholecystitis and cholestasis caused by UDCA. In addition, increasing awareness about this drug among patients suffering from gallstones is expected to drive growth during the forecast period.
The biliary disease segment is anticipated to witness significant growth over the forecast period due to an increase in cases of jaundice and liver cancer caused by hepatitis B virus (HBV). In addition, t-UDCA has been found effective against HBV infection as well as its related complications such as chronic hepatitis & hepatocellular carcinoma (HCC). Thus rising incidences of these diseases are expected fuel demand for UDCA during the forecast period.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period due to increasing prevalence of biliary diseases and hepatoopathies. Rising awareness regarding liver health, rising disposable income, and high adoption of nutritional products are some factors responsible for regional growth.
Asia Pacific is anticipated to be one of the fastest-growing regions over the forecast period owing to an increase in healthcare expenditure by 2% every year as compared with other developing countries such as India and China. Moreover, growing medical tourism industry in emerging economies such as India & China will drive demand for UDCA drugs over the next eight years.
Latin America also has a significant share owing to an increase in prevalence of gallstone disease coupled with rise in consumer awareness about drug safety & efficacy especially after FDA approval process completion (t-UDCA).
Growth Factors:
- Increasing prevalence of liver diseases: The global prevalence of liver diseases is increasing at a rapid pace. This is primarily attributed to the changing lifestyle and dietary habits, which are leading to an increase in the number of people suffering from obesity and other chronic liver diseases. According to a study by the World Health Organization (WHO), approximately 1.3 billion adults were overweight in 2016, and this number is expected to rise further in the coming years. This will create a large pool of patients who will require treatment for various forms of liver disease, including those caused by alcohol abuse, viral hepatitis, and non-alcoholic fatty liver disease (NAFLD). As such, there is considerable potential for growth for drugs that can effectively treat these conditions, such as UDCA and t-UDCA.
- Growing awareness about benefits of UDCA therapy: There has been growing awareness among healthcare professionals about the benefits of using UDCA therapy for treating various forms of chronic liver disease. This has led to an increase in demand for drugs that contain UDCA as one their active ingredients across regions worldwide. In addition, there has been an increase in demand from patients who are looking for alternative treatments options that can help improve their quality life without causing any major side effects. All these factors are likely to contribute significantly towards growth prospects for drugs containing UDCA over the forecast period
Scope Of The Report
Report Attributes
Report Details
Report Title
Drugs of UDCA and t-UDCA Market Research Report
By Type
t-UDCA, UDCA
By Application
Gallstone, Hepatopathy, Biliary Disease, Other
By Companies
Dr. Falk Pharma, Daewoong Pharmaceutical, Teva, Epic Pharma, Mitsubishi Tanabe Pharma, Lannett, Mylan, Bruschettini, Impax, Shanghai Pharma, Grindeks
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
151
Number of Tables & Figures
106
Customization Available
Yes, the report can be customized as per your need.
Global Drugs of UDCA and t-UDCA Market Report Segments:
The global Drugs of UDCA and t-UDCA market is segmented on the basis of:
Types
t-UDCA, UDCA
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Gallstone, Hepatopathy, Biliary Disease, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Dr. Falk Pharma
- Daewoong Pharmaceutical
- Teva
- Epic Pharma
- Mitsubishi Tanabe Pharma
- Lannett
- Mylan
- Bruschettini
- Impax
- Shanghai Pharma
- Grindeks
Highlights of The Drugs of UDCA and t-UDCA Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- t-UDCA
- UDCA
- By Application:
- Gallstone
- Hepatopathy
- Biliary Disease
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Drugs of UDCA and t-UDCA Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Drugs of UDCA and t-UDCA are synthetic cannabinoids. They are similar to the psychoactive compound THC, but they have a different chemical structure. This difference makes them difficult to break down by the body, which is why they have a longer effect than THC.
Some of the major companies in the drugs of udca and t-udca market are Dr. Falk Pharma, Daewoong Pharmaceutical, Teva, Epic Pharma, Mitsubishi Tanabe Pharma, Lannett, Mylan, Bruschettini, Impax, Shanghai Pharma, Grindeks.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Drugs of UDCA and t-UDCA Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Drugs of UDCA and t-UDCA Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Drugs of UDCA and t-UDCA Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Drugs of UDCA and t-UDCA Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Drugs of UDCA and t-UDCA Market Size & Forecast, 2020-2028
4.5.1 Drugs of UDCA and t-UDCA Market Size and Y-o-Y Growth
4.5.2 Drugs of UDCA and t-UDCA Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 t-UDCA
5.2.2 UDCA
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Gallstone
6.2.2 Hepatopathy
6.2.3 Biliary Disease
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Drugs of UDCA and t-UDCA Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Drugs of UDCA and t-UDCA Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 t-UDCA
9.6.2 UDCA
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Gallstone
9.10.2 Hepatopathy
9.10.3 Biliary Disease
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 t-UDCA
10.6.2 UDCA
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Gallstone
10.10.2 Hepatopathy
10.10.3 Biliary Disease
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 t-UDCA
11.6.2 UDCA
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Gallstone
11.10.2 Hepatopathy
11.10.3 Biliary Disease
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 t-UDCA
12.6.2 UDCA
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Gallstone
12.10.2 Hepatopathy
12.10.3 Biliary Disease
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 t-UDCA
13.6.2 UDCA
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Gallstone
13.10.2 Hepatopathy
13.10.3 Biliary Disease
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Drugs of UDCA and t-UDCA Market: Competitive Dashboard
14.2 Global Drugs of UDCA and t-UDCA Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Dr. Falk Pharma
14.3.2 Daewoong Pharmaceutical
14.3.3 Teva
14.3.4 Epic Pharma
14.3.5 Mitsubishi Tanabe Pharma
14.3.6 Lannett
14.3.7 Mylan
14.3.8 Bruschettini
14.3.9 Impax
14.3.10 Shanghai Pharma
14.3.11 Grindeks
